Skip to content
The Chat Archive
mistral-medium· Mistral AI Arena Human Preference 55K

Otezla mechanism of action and pharmacology/pharmacokinetics

  1. User

    Otezla mechanism of action and pharmacology/pharmacokinetics

  2. Assistant

    Otezla (apremilast) is an oral medication used to treat plaque psoriasis, psoriatic arthritis, and Behçet's disease. Its mechanism of action involves inhibiting phosphodiesterase 4 (PDE4), an enzyme that breaks down cyclic adenosine monophosphate (cAMP) within cells. By inhibiting PDE4, apremilast increases intracellular cAMP levels, which in turn leads to reduced production of pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interleukin-23 (IL-23). This anti-inflammatory effect helps to alleviate the symptoms of psoriasis, psoriatic arthritis, and Behçet's disease.

    Pharmacokinetics of Otezla:

    1. Absorption: Apremilast is rapidly absorbed following oral administration, with peak plasma concentrations occurring approximately 2 hours after dosing. Food does not significantly affect its bioavailability.
    2. Distribution: The volume of distribution of apremilast is approximately 760 L, indicating extensive distribution into tissues. It is highly bound (>99%) to plasma proteins, mainly albumin.
    3. Metabolism: Apremilast is primarily metabolized by the enzyme UGT1A3 and, to a lesser extent, by UGT1A8 and UGT1A9, into inactive metabolites.
    4. Elimination: The elimination half-life of apremilast is approximately 6-9 hours. It is excreted mainly in the feces (approximately 73%) as metabolites, and to a lesser extent in the urine (approximately 22%).
    5. Dosage: The recommended starting dose of Otezla is 10 mg twice daily, which is increased to 20 mg twice daily after the first week. For patients with severe renal impairment, the recommended starting dose is 10 mg once daily, which is increased to 10 mg twice daily after the first week. For patients with moderate hepatic impairment, the recommended dose is 10 mg twice daily.
    6. Drug interactions: Apremilast is a substrate of cytochrome P450 (CYP) enzymes, but it is not a significant inducer or inhibitor of CYP enzymes. Therefore, drug interactions due to CYP-mediated metabolism are not expected to be clinically relevant. However, apremilast may increase the plasma concentrations of CYP2C8 substrates such as repaglinide, and caution is advised when co-administering these medications. Additionally, concomitant use of strong CYP3A4 inducers such as rifampin may decrease the plasma concentrations of apremilast, potentially reducing its therapeutic effect.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.